Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 1/2019

Ausgabe 1/2019

Inhaltsverzeichnis ( 22 Artikel )

18.04.2018 | PRECLINICAL STUDIES | Ausgabe 1/2019 Open Access

Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate

Catherine M. E. Barnett, Natasa Broit, Pei-Yi Yap, Jason K. Cullen, Peter G. Parsons, Benedict J. Panizza, Glen M. Boyle

26.04.2018 | PRECLINICAL STUDIES | Ausgabe 1/2019

Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides

Tammy Price-Troska, Zhi-Zhang Yang, David Diller, Alexander Bayden, Mark Jarosinski, Joseph Audie, Stephen M. Ansell

02.05.2018 | PRECLINICAL STUDIES | Ausgabe 1/2019

Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists

A. Molinos-Quintana, P. Trujillo-Hacha, J. I. Piruat, J. A. Bejarano-García, E. García-Guerrero, J. A. Pérez-Simón, Miguel Muñoz

15.05.2018 | PRECLINICAL STUDIES | Ausgabe 1/2019

Copper-tolfenamic acid: evaluation of stability and anti-cancer activity

Myrna Hurtado, Umesh T. Sankpal, Jaya Chhabra, Deondra T. Brown, Rajasekhar Maram, Rafid Patel, Raj K. Gurung, Jerry Simecka, Alvin A. Holder, Riyaz Basha

19.05.2018 | PRECLINICAL STUDIES | Ausgabe 1/2019 Open Access

Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology – phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells

Mateusz Psurski, Agnieszka Łupicka-Słowik, Agnieszka Adamczyk-Woźniak, Joanna Wietrzyk, Andrzej Sporzyński

28.05.2018 | PRECLINICAL STUDIES | Ausgabe 1/2019

Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer

Maha M. Eissa, Cherine A. Ismail, Mervat Z. El-Azzouni, Amany A. Ghazy, Mona A. Hadi

02.06.2018 | PRECLINICAL STUDIES | Ausgabe 1/2019

Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells

Shujun Xiao, Jian Yang

06.06.2018 | PRECLINICAL STUDIES | Ausgabe 1/2019

The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer

Mei Tang, Qiuli Liu, Leyuan Zhou, Ling Chen, Xueqing Yang, Jinjin Yu, Yuan Wang, Haifeng Qiu

18.04.2018 | PHASE I STUDIES | Ausgabe 1/2019

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules

Kamalesh Sankhala, Chris H. Takimoto, Alain C. Mita, Henry Xiong, Jordi Rodón, Amir Mehrvarz Sarshekeh, K. Burns, Kenzo Iizuka, Scott Kopetz

21.05.2018 | PHASE I STUDIES | Ausgabe 1/2019 Open Access

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

A Craig Lockhart, Todd M. Bauer, Charu Aggarwal, Carrie B. Lee, R Donald Harvey, Roger B. Cohen, Farhad Sedarati, Tsz Keung Nip, Hélène Faessel, Ajeeta B. Dash, Bruce J. Dezube, Douglas V. Faller, Afshin Dowlati

09.06.2018 | PHASE I STUDIES | Ausgabe 1/2019

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

Manuel Ruiz-Borrego, Begoña Jimenez, Silvia Antolín, Jose A. García-Saenz, Jesús Corral, Yolanda Jerez, José Trigo, Ander Urruticoechea, Helena Colom, Nuria Gonzalo, Carmen Muñoz, Sara Benito, Rosalía Caballero, Susana Bezares, Eva Carrasco, Federico Rojo, Miguel Martín

11.07.2018 | PHASE I STUDIES | Ausgabe 1/2019

Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer

Masafumi Ikeda, Izumi Ohno, Hideki Ueno, Shuichi Mitsunaga, Yusuke Hashimoto, Takuji Okusaka, Shunsuke Kondo, Mitsuhito Sasaki, Yasunari Sakamoto, Hideaki Takahashi, Rina Hara, Shingo Kobayashi, Osamu Nakamura, Chigusa Morizane

11.07.2018 | PHASE I STUDIES | Ausgabe 1/2019 Open Access

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma

Masafumi Ikeda, Manabu Morimoto, Masaomi Tajimi, Koichi Inoue, Karim A. Benhadji, Michael M. F. Lahn, Daisuke Sakai

12.07.2018 | PHASE I STUDIES | Ausgabe 1/2019

Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial

Christian Dittrich, Robert Königsberg, Martina Mittlböck, Klaus Geissler, Azra Sahmanovic-Hrgovcic, Johannes Pleiner-Duxneuner, Martin Czejka, Philipp Buchner

21.07.2018 | PHASE I STUDIES | Ausgabe 1/2019

Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects

Zhi-Yi Zhang, Jing Wang, Vikram Kansra, Xiaodong Wang

28.07.2018 | PHASE I STUDIES | Ausgabe 1/2019

First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors

Kathleen N. Moore, Johanna C. Bendell, Patricia M. LoRusso, Anthony J. Olszanski, Esther Zwick-Wallasch, Mendel Jansen, Alexander G. Vandell, Giorgio Senaldi

30.07.2018 | SHORT REPORT | Ausgabe 1/2019 Open Access

Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma

Kimmie Ng, Andrew Hendifar, Alexander Starodub, Jorge Chaves, Yingsi Yang, Brian Koh, David Barbie, William C. Hahn, Charles S. Fuchs

07.08.2018 | REVIEW | Ausgabe 1/2019

Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991–2015

Kota Itahashi, Toshio Shimizu, Takafumi Koyama, Shunsuke Kondo, Yutaka Fujiwara, Noboru Yamamoto

24.10.2018 | REVIEW | Ausgabe 1/2019

Advanced development of ErbB family-targeted therapies in osteosarcoma treatment

Wei Wang, Hua-fu Zhao, Teng-fei Yao, Hao Gong

03.07.2018 | SHORT REPORT | Ausgabe 1/2019

Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein

Takahisa Kawamura, Haruyasu Murakami, Haruki Kobayashi, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Masahiro Endo, Toshiaki Takahashi

22.10.2018 | SHORT REPORT | Ausgabe 1/2019

Antitumor evaluation of novel phenothiazine derivatives that inhibit migration and tubulin polymerization against gastric cancer MGC-803 cells

Nan Liu, Zhe Jin, Jing Zhang, Jianjun Jin

16.01.2019 | ACKNOWLEDGEMENTS | Ausgabe 1/2019

Acknowledgement of Reviewers 2018

Aktuelle Ausgaben


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise